Mahmut ULUBAY, Mustafa Kemal ATİLLA, Bahattin AVCI, Alper BİTKİN, Mevlüt KELEŞ, İnci YÜCEL, Lokman İRKILATA, Mustafa AYDIN

Does transrectal ultrasonography-guided biopsy of the prostate lead to possible further metastasis via circulating tumor cells?

Background/aim: We evaluate whether transrectal ultrasonography (TRUS)-guided prostate biopsy might lead to spillage of tumor cellsinto peripheral blood as a result of disruption of the epithelial barrier and ultimately result in metastasis.Materials and methods: Eighty-eight patients underwent TRUS-guided prostate needle biopsy due to prostate-specific antigen (PSA)increase or abnormal digital rectal examination at the Samsun Research and Training Hospital (Samsun, Turkey) between April 2016and September 2018. Approximately 10 mL of whole blood was collected from patients before, 1 week after, and 1 month after biopsy.Samples were analyzed for CD117 positivity and prostate-specific membrane antigen (PSMA) levels using flow cytometry. Patients withpathologically determined prostate cancer and without CD117 positivity before biopsy were included in the study. The study group thusconsisted of 55 patients.Results: Subjects’ PSA levels ranged from 2.3 to 40.0 ng/mL (median: 7.9 ng/mL), and their Gleason score was a median of 7 (range:5–9). PSMA levels ranged between 9.3 ng/mL and 118.5 ng/mL and CD117 antigen levels between 0 and 5. We detected no CD117-positive cells in blood samples collected 7 days or 1 month after biopsy.Conclusion: We detected no circulating tumor cells in the peripheral circulation following biopsy. Prostate needle biopsy seems to be asafe method in terms of spillage of tumor cells into blood circulation as a possible cause of further metastasis.

PDF

___

1. Handy CE, Antonarakis ES. Sequencing treatment for castration-resistant prostate cancer. Current Treatment Options in Oncology 2016; 17: 64. doi: 10.1007/s11864-016-0438-9
2. Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. Journal of Urology 1989; 142: 66-70. doi: 10.1016/s0022- 5347(17)38663-9
3. Müller V, Stahmann N, Riethdorf S, Rau T, Zabel T et al. Circulating tumor cells in breast cancer: correlation to bone marrow micro metastases, heterogeneous response to systemic therapy and low proliferative activity. Clinical Cancer Research 2005; 11: 3678-3685. doi: 10.1158/1078-0432.CCR-04-2469
4. Witte ON. Steel locus defines new multipotent growth factor. Cell 1990; 63: 5-6. doi: 10.1016/0092-8674(90)90280-r
5. Yarden Y, Kuang WJ, Yang Feng T, Coussens L, Munemitsu S et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO Journal 1987; 6: 3341-3351.
6. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. Journal of Clinical Oncology 2002; 20: 1692-1703. doi: 10.1200/ JCO.2002.20.6.1692
7. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991; 78: 2962-2968.
8. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clinical Cancer Research 1996; 2: 1445-1451.
9. Leek J, Lench N, Maraj B, Bailey A, Carr IM et al. Prostatespecific membrane antigen: evidence for the existence of a second related human gene. British Journal of Cancer 1995; 72: 583-588. doi: 10.1038/bjc.1995.377
10. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256–2261. doi: 10.1002(sici)1097- 0142(19980601)82::11<2256:aid-cncr22>3.0.co:2-s
11. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P et al. Detection of hematogenous micro metastasis in patients with prostate cancer. Cancer Research 1992; 52: 6110-6112.
12. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research 2008; 14: 6302-6309. doi: 10.1158/1078-0432.CCR-08-0872
13. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical Cancer Research 2004; 10: 6897-6904. doi: 10.1158/1078-0432.CCR-04-0378
14. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology 2009; 10: 233-239. doi: 10.1016/ S1470-2045(08)70340-1
15. Beitsch PD, Clifford E. Detection of carcinoma cells in the blood of breast cancer patients. American Journal of Surgery 2000; 180: 446-448. doi: 10.1016/s0002-9610(00)00518-3
16. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clinical Cancer Research 2007; 13: 920- 928. doi: 10.1158/1078-0432.CCR-06-1695
17. Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Current Treatment Options in Oncology 2010; 11: 1-13. doi: 10.1007/s11864-010- 0115-3
18. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clinical Cancer Research 2011; 17: 3903-3912. doi: 10.1158/1078-0432.CCR-10-2650
19. Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. Journal of Urology 2008; 179: 2187-2191. doi: 10.1016/j.juro.2008.01.102
20. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery 2012; 2: 995-1003. doi: 10.1158/2159-8290.CD-12- 0222
21. Chang SS. Overview of prostate-specific membrane antigen. Reviews in Urology 2004; 6 (Suppl. 10): S13-18.
22. Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ et al. Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth. International Journal of Cancer 2015; 136: 11-20. doi: 10.1002/ijc.28948
23. Bhagwat N, Carpenter EL. Flow cytometric methods for circulating tumor cell isolation and molecular analysis. Advances in Experimental Medicine and Biology 2017; 994: 105-118. doi: 10.1007/978-3-319-55947-6_5